Enzo Biochem Balance Sheet Health
Financial Health criteria checks 5/6
Enzo Biochem has a total shareholder equity of $70.8M and total debt of $3.5M, which brings its debt-to-equity ratio to 5%. Its total assets and total liabilities are $99.1M and $28.3M respectively.
Key information
5.0%
Debt to equity ratio
US$3.53m
Debt
Interest coverage ratio | n/a |
Cash | US$60.24m |
Equity | US$70.78m |
Total liabilities | US$28.30m |
Total assets | US$99.08m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: EZB's short term assets ($80.9M) exceed its short term liabilities ($25.3M).
Long Term Liabilities: EZB's short term assets ($80.9M) exceed its long term liabilities ($3.0M).
Debt to Equity History and Analysis
Debt Level: EZB has more cash than its total debt.
Reducing Debt: EZB's debt to equity ratio has reduced from 7.4% to 5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EZB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EZB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 35.8% each year